Skip to main content

Table 2 PDX models of triple-negative breast cancers

From: Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

PDX Patient sourcea Patient treatmentb HER2 statusc ER status PR status EGFR H-scored BCL-2 H-scoree BCL-XL H-score
HCI-001 PT + Prior T× 188 10 100
HCI-002 PT − Prior T× 121 230 90
HCI-004 PT − Prior T× 76 10 220
HCI-010 PE + Prior T× 228 10 10
HCI-015 MT + Prior T× 193 20 60
HCI-016 PT − Prior T× 90 280 90
HCI-019 PT − Prior T× 208 40 155
  1. aPT primary breast tumor, PE pleural effusion, MT metastatic breast tumor
  2. bT×, treatment as previously described [16] and unpublished data kindly provided by A.W.
  3. cHER2, ER, and PR as previously described [16] and unpublished data kindly provided by A.W.
  4. dH-score represents the average of 4–6 tumors per PDX
  5. eH-score represents one tumor surveyed per PDX kindly provided by A.W.